APA (7th ed.) Citation

Müller, A. R., den Hollander, B., van de Ven, P. M., Roes, K. C. B., Geertjens, L., Bruining, H., . . . van Eeghen, A. M. (2024). Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: Protocol for a series of randomized, placebo-controlled N-of-1 trials. BMC Psychiatry, 24(1), 1. https://doi.org/10.1186/s12888-023-05422-3

Chicago Style (17th ed.) Citation

Müller, A. R., et al. "Cannabidiol (Epidyolex®) for Severe Behavioral Manifestations in Patients with Tuberous Sclerosis Complex, Mucopolysaccharidosis Type III and Fragile X Syndrome: Protocol for a Series of Randomized, Placebo-controlled N-of-1 Trials." BMC Psychiatry 24, no. 1 (2024): 1. https://doi.org/10.1186/s12888-023-05422-3.

MLA (9th ed.) Citation

Müller, A. R., et al. "Cannabidiol (Epidyolex®) for Severe Behavioral Manifestations in Patients with Tuberous Sclerosis Complex, Mucopolysaccharidosis Type III and Fragile X Syndrome: Protocol for a Series of Randomized, Placebo-controlled N-of-1 Trials." BMC Psychiatry, vol. 24, no. 1, 2024, p. 1, https://doi.org/10.1186/s12888-023-05422-3.